66. IgA腎症 IgA nephropathy Clinical trials / Disease details


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05065970
(ClinicalTrials.gov)
August 31, 202114/9/2021Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA NephropathyImmunoglobulin A (IgA) NephropathyDrug: Felzartamab;Other: PlaceboMorphoSys AGNULLRecruiting18 Years80 YearsAll48Phase 2United States;Australia;Belgium;Bulgaria;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom
2EUCTR2020-005054-19-DE
(EUCTR)
16/08/202101/04/2021A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ IgA Nephropathy (IgAN)
MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Felzartamab
Product Code: MOR202
INN or Proposed INN: Felzartamab
Other descriptive name: MOR03087
MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 2Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of
3EUCTR2020-005054-19-CZ
(EUCTR)
28/07/202109/03/2021A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ IgA Nephropathy (IgAN)
MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Felzartamab
Product Code: MOR202
INN or Proposed INN: Felzartamab
Other descriptive name: MOR03087
MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 2Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of
4EUCTR2020-005054-19-ES
(EUCTR)
08/07/202109/07/2021A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ IgA Nephropathy (IgAN)
MedDRA version: 23.1;Level: PT;Classification code 10084204;Term: Sickle cell nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Felzartamab
Product Code: MOR202
INN or Proposed INN: Felzartamab
Other descriptive name: MOR03087
MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44Phase 2Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of
5EUCTR2020-005054-19-BE
(EUCTR)
30/06/202107/05/2021A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ IgA Nephropathy (IgAN)
MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Felzartamab
Product Code: MOR202
INN or Proposed INN: Felzartamab
Other descriptive name: MOR03087
MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 2United States;Serbia;Philippines;Czechia;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Belgium;Malaysia;Australia;Georgia;Bulgaria;Germany;Japan;Korea, Republic of
6EUCTR2020-005054-19-BG
(EUCTR)
30/06/202118/03/2021A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA NephropathyA Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ IgA Nephropathy (IgAN)
MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Felzartamab
Product Code: MOR202
INN or Proposed INN: Felzartamab
Other descriptive name: MOR03087
MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 2Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of